A Phase 3 interventional study of Meningococcal group B Vaccine, rMenB+OMV NZ and Meningococcal ACWY Conjugate Vaccine, MenACWY in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 7 sites in 2 countries. Open to participants aged 85 Days to 119 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-22.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 10th largest by enrollment, is one of 3 that started in 2014, is one of 7 in phase 3, and was the 12th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 85 Days to 119 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 9 · Phase 4 4
First in 2006; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 750 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 508 across the 21 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
71 studies in Meningococcal Infections by GlaxoSmithKline: none open now, 1 under way, none of them phase 3. Of 70 finished, 60 (86%) have results posted.
Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, this one is the 27th largest by enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2014, is one of 34 in phase 3, and was the 49th registered.
GlaxoSmithKline’s Meningococcal Infections studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 71 in Meningococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate the immunogenicity, the safety and the tolerability of rMenB+OMV NZ and MenACWY vaccines in healthy infants, when concomitantly administered at 3, 5, 7 and 13 months of age, compared to either alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Known or suspected disease or impairment/alteration of the immune system resulting from, for ex-ample:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
Biological: Meningococcal group B Vaccine, rMenB+OMV NZ · Biological: Meningococcal ACWY Conjugate Vaccine, MenACWY
Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
Biological: Meningococcal group B Vaccine, rMenB+OMV NZ
Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
Biological: Meningococcal ACWY Conjugate Vaccine, MenACWY
Drug page: 4CMenB vaccine
4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
Also known as: Bexsero®
4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
Also known as: Menveo®
Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against Each of the Serogroup B Indicator Strains
Human serum bactericidal activity (hSBA) titers against each of the serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 after receiving 4 doses of rMenB+OMV NZ / MenACWY vaccines, concomitantly administered, versus corresponding response in subjects who received rMenB+OMV NZ administered alone, were presented in terms of vaccine group specific geometric mean titers (GMTs). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
Time frame: At Day 331 (one month after the fourth vaccination)
hSBA Geometric Mean Titers (GMTs) Against Each of the Serogroups A, C, W-135 and Y
hSBA titers against N. meningitidis serogroups A, C, W-135 and Y after receiving four doses of either rMenB+OMV NZ / MenACWY concomitantly administered versus corresponding response in subjects who received MenACWY administered alone were presented in terms of vaccine group specific GMTs. This outcome measure applies to only rMenB+ACWY and MenACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.
Time frame: At Day 331 (one month after the fourth vaccination)
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.
hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
Time frame: At Day 1
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.
hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
Time frame: At Day 151 (one month after the third vaccination)
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.
hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
Time frame: At Day 301 (before the fourth vaccination)
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.
hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
Time frame: At Day 331 (one month after the fourth vaccination)
hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.
hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.
Time frame: At Day 1
hSBA Geometric Mean Titers Against Each of the Serogroups A, C, W-135 and Y
hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.
Time frame: At Day 151 (one month after the third vaccination)
hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.
hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.
Time frame: At Day 301 (before the fourth vaccination)
hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.
hSBA GMTs against each of the N.meningitidis serogroups A, C, W-135, Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.
Time frame: At Day 331 (one month after the fourth vaccination)
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Indicator Strains
Percentage of subjects with hSBA titers≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 before the first vaccination (Day 1). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
Time frame: At Day 1
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Indicator Strains
Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
Time frame: At Day 151 (one month after the third vaccination)
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Strains.
Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
Time frame: At Day 301 (before the fourth vaccination)
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Strains.
Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
Time frame: At Day 331 (One month after the fourth vaccination)
Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains
Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
Time frame: At Day 1
Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains
Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains at one month after third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
Time frame: At Day 151 (one month after the third vaccination)
Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains
Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
Time frame: At Day 301 (before the fourth vaccination)
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroup B Indicator Strains
Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
Time frame: At Day 331 (one month after the fourth vaccination)
Percentage of Subjects With hSBA Titers ≥1:4 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y before the first vaccination (Day 1). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
Time frame: At Day 1
Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
Time frame: At Day 151 (one month after the third vaccination)
Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
Time frame: At Day 301 (before the fourth vaccination)
Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
Time frame: At Day 331 (one month after the fourth vaccination)
Within-subject Geometric Mean Ratios (GMRs) Against Each of the Serogroup B Indicator Strains
Geometric Mean Ratios(GMRs) of GMTs against each of the serogroup B indicator strains- H44/76, 5/99, N98/254 \& M10713 were calculated at one month after the fourth vaccination (Day 331) versus pre fourth vaccination(Day 301).
Time frame: At Day 331 (one month after fourth vaccination)
Within-subject Geometric Mean Ratios (GMRs) Against Each of Serogroups A, C, W-135 and Y
Geometric Mean Ratios(GMRs) of GMTs against each of the serogroups A,C,W-135 \& Y were calculated at one month after the fourth vaccination (Day 331) versus pre fourth vaccination (Day 301).
Time frame: At Day 331 (one month after the fourth vaccination)
Percentage of Subjects With Four-fold Increases in hSBA Titers Against Each of the Serogroup B Indicator Strains
Percentage of subjects with four-fold increase in hSBA titers against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331) over pre-fourth vaccination (Day 301). This outcome measure applies to only groups rMenB+ACWY and rMenB as the serogroup B indicator strains were assessed only for these two groups. For serogroup B strains, 4-fold increase in titers was defined as post 4th vaccination titer ≥8 (if pre 4th vaccination titer was \<2) or post 4th vaccination titer ≥ 4 x pre 4th vaccination titer (if pre 4th vaccination titer was ≥2).
Time frame: At Day 331 (one month after the fourth vaccination)
Percentage of Subjects With Four-fold Increases in hSBA Titers Against Each of the Serogroups A, C, W-135 and Y
Percentages of subjects with four-fold increases in hSBA against each of the N. meningitidis serogroups A,C,W \& Y at one month after the fourth vaccination (Day 331) over pre-fourth vaccination(Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups. For serogroups A, C, W and Y, 4-fold increase in titers was defined as post 4th vaccination titer ≥16 (if pre 4th vaccination titer was \<4) or post 4th vaccination titer ≥ 4 x pre 4th vaccination titer (if pre 4th vaccination titer was ≥4).
Time frame: At Day 331 (one month after the fourth vaccination)
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 and Y at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
Time frame: At Day 1
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
Time frame: At Day 151 (one month before the third vaccination)
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
Time frame: At Day 301 (before the fourth vaccination)
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
Time frame: At Day 331 (one month after the fourth vaccination)
Number of Subjects With Solicited Local and Systemic Adverse Events (AEs)
Number of subjects with solicited local and systemic AEs during the 7 days (including the day of vaccination) after any vaccination
Time frame: From Day 1 (6 hours) to Day 7 after each vaccination (Days 1, 61, 121 and 301)
Number of Subjects With Unsolicited Adverse Events
An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.
Time frame: From Day 1 to Day 7 after each vaccination (Days 1, 61, 121 and 301)
Number of Subjects With SAEs, AEs Leading to Withdrawal and Medically Attended AEs (MAEs)
A serious adverse event is any untoward medical occurrence that at any dose results in death/ is life threatening/requires prolonged hospitalization/Persistent or significant disability/incapacity/congenital anomaly/or birth defect.
Time frame: Throughout the whole study period (from Day 1 upto Day 331)
750 healthy infants, aged 3 months were recruited from 3 sites in Argentina and 4 sites in Mexico.
| Milestone | rMenB+ACWY Group | rMenB Group | MenACWY Group |
|---|---|---|---|
| Started | 252 | 250 | 248 |
| Completed | 203 | 202 | 205 |
| Not completed | 49 | 48 | 43 |
| Withdrew: Withdrawal by subject | 15 | 16 | 15 |
| Withdrew: Lost to follow-up | 25 | 20 | 13 |
| Withdrew: Other: administrative reason | 8 | 5 | 12 |
| Withdrew: Other: unspecified | 1 | 4 | 2 |
| Withdrew: Adverse event | 0 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
Human serum bactericidal activity (hSBA) titers against each of the serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 after receiving 4 doses of rMenB+OMV NZ / MenACWY vaccines, concomitantly administered, versus corresponding response in subjects who received rMenB+OMV NZ administered alone, were presented in terms of vaccine group specific geometric mean titers (GMTs). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
| Titers | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 92 (67 to 128) | 104 (77 to 141) |
| 5/99 | 1850 (1122 to 3050) | 1790 (1128 to 2842) |
| NZ98/254 | 39 (29 to 53) | 38 (28 to 52) |
| M10713 | 13 (7.82 to 21) | 12 (7.72 to 20) |
hSBA titers against N. meningitidis serogroups A, C, W-135 and Y after receiving four doses of either rMenB+OMV NZ / MenACWY concomitantly administered versus corresponding response in subjects who received MenACWY administered alone were presented in terms of vaccine group specific GMTs. This outcome measure applies to only rMenB+ACWY and MenACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.
| Titers | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 409 (300 to 556) | 165 (122 to 224) |
| Serogroup C | 452 (312 to 655) | 421 (294 to 602) |
| Serogroup W | 721 (493 to 1053) | 536 (370 to 776) |
| Serogroup Y | 410 (293 to 575) | 391 (280 to 546) |
hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
| Titers | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 1.03 (0.99 to 1.08) | 1.02 (0.98 to 1.07) |
| 5/99 | 1.09 (0.99 to 1.21) | 1.07 (0.97 to 1.17) |
| NZ98/254 | 1.06 (1.01 to 1.12) | 1.07 (1.02 to 1.12) |
| M10713 | 1.88 (1.51 to 2.34) | 1.59 (1.29 to 1.96) |
hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
| Titers | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 116 (100 to 135) | 129 (113 to 147) |
| 5/99 | 891 (752 to 1055) | 935 (803 to 1088) |
| NZ98/254 | 32 (26 to 39) | 33 (27 to 40) |
| M10713 | 9.09 (6.57 to 13) | 10 (7.50 to 14) |
hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
| Titers | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 7.68 (5.91 to 9.99) | 8.31 (6.54 to 11) |
| 5/99 | 131 (107 to 161) | 109 (90 to 132) |
| NZ98/254 | 3.21 (2.44 to 4.21) | 2.93 (2.25 to 3.81) |
| M10713 | 2.48 (1.89 to 3.27) | 2.40 (1.85 to 3.10) |
hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
| Titers | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 122 (98 to 151) | 126 (104 to 154) |
| 5/99 | 1404 (1016 to 1939) | 1262 (934 to 1706) |
| NZ98/254 | 37 (30 to 45) | 36 (30 to 44) |
| M10713 | 18 (14 to 24) | 17 (13 to 22) |
hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.
| Titers | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 2.05 (1.97 to 2.15) | 2.08 (1.99 to 2.17) |
| Serogroup C | 2.16 (1.98 to 2.35) | 2.09 (1.92 to 2.27) |
| Serogroup W | 2.33 (2.13 to 2.55) | 2.31 (2.11 to 2.52) |
| Serogroup Y | 2.06 (1.95 to 2.17) | 2.16 (2.05 to 2.28) |
hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.
| Titers | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 303 (242 to 379) | 136 (108 to 169) |
| Serogroup C | 388 (320 to 469) | 416 (345 to 502) |
| Serogroup W | 347 (282 to 427) | 298 (244 to 364) |
| Serogroup Y | 226 (182 to 282) | 283 (228 to 351) |
hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.
| Titers | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 20 (15 to 28) | 15 (11 to 21) |
| Serogroup C | 31 (23 to 41) | 43 (32 to 58) |
| Serogroup W | 48 (37 to 63) | 47 (36 to 62) |
| Serogroup Y | 38 (30 to 49) | 43 (33 to 55) |
hSBA GMTs against each of the N.meningitidis serogroups A, C, W-135, Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.
| Titers | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 329 (269 to 403) | 132 (108 to 161) |
| Serogroup C | 331 (268 to 409) | 311 (252 to 384) |
| Serogroup W | 576 (458 to 723) | 428 (342 to 537) |
| Serogroup Y | 377 (304 to 466) | 363 (294 to 448) |
Percentage of subjects with hSBA titers≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 before the first vaccination (Day 1). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 0 (0.0 to 2.3) | 1 (0.01 to 2.8) |
| 5/99 | 1 (0.15 to 4.5) | 1 (0.13 to 3.7) |
| NZ98/254 | 1 (0.01 to 2.9) | 1 (0.01 to 2.7) |
| M10713 | 16 (11.4 to 22.7) | 11 (6.9 to 15.9) |
Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 100 (97.6 to 100.0) | 100 (98.2 to 100.0) |
| 5/99 | 100 (97.3 to 100.0) | 100 (98.1 to 100.0) |
| NZ98/254 | 96 (92.2 to 98.4) | 97 (93.7 to 98.9) |
| M10713 | 70 (62.7 to 77.0) | 68 (61.1 to 74.3) |
Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 74 (65.4 to 81.2) | 75 (67.9 to 80.7) |
| 5/99 | 100 (97.4 to 100.0) | 97 (93.9 to 99.1) |
| NZ98/254 | 42 (34.2 to 49.3) | 36 (29.7 to 43.3) |
| M10713 | 33 (25.7 to 41.2) | 31 (24.5 to 37.7) |
Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 100 (97.4 to 100.0) | 99 (97.1 to 99.99) |
| 5/99 | 99 (95.0 to 99.83) | 97 (93.0 to 98.8) |
| NZ98/254 | 100 (98.0 to 100.0) | 98 (94.9 to 99.4) |
| M10713 | 87 (80.8 to 91.7) | 87 (81.6 to 91.5) |
Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 0 (0.0 to 2.3) | 0 (0.0 to 1.8) |
| 5/99 | 1 (0.02 to 3.5) | 1 (0.01 to 2.9) |
| NZ98/254 | 1 (0.01 to 2.9) | 1 (0.01 to 2.7) |
| M10713 | 12 (7.3 to 17.1) | 8 (4.6 to 12.5) |
Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains at one month after third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 100 (97.6 to 100.0) | 100 (98.2 to 100.0) |
| 5/99 | 100 (97.3 to 100.0) | 100 (98.1 to 100.0) |
| NZ98/254 | 92 (87.4 to 95.7) | 92 (87.6 to 95.5) |
| M10713 | 65 (57.2 to 72.1) | 59 (52.2 to 66.0) |
Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 58 (49.5 to 67.0) | 56 (48.9 to 63.5) |
| 5/99 | 100 (97.4 to 100.0) | 97 (93.2 to 98.8) |
| NZ98/254 | 26 (19.6 to 33.2) | 26 (20.6 to 33.1) |
| M10713 | 21 (14.4 to 27.9) | 23 (17.5 to 29.7) |
Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 100 (97.4 to 100.0) | 99 (97.1 to 99.99) |
| 5/99 | 99 (95.0 to 99.83) | 97 (93.0 to 98.8) |
| NZ98/254 | 98 (94.4 to 99.4) | 94 (90.2 to 97.2) |
| M10713 | 83 (76.5 to 88.6) | 82 (76.4 to 87.5) |
Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y before the first vaccination (Day 1). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 1 (0.11 to 3.4) | 1 (0.12 to 3.5) |
| Serogroup C | 4 (1.7 to 7.5) | 3 (1.4 to 6.9) |
| Serogroup W | 4 (1.8 to 8.0) | 4 (1.4 to 7.2) |
| Serogroup Y | 2 (0.5 to 4.7) | 5 (2.3 to 8.6) |
Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 99 (97.4 to 99.99) | 96 (92.0 to 98.0) |
| Serogroup C | 100 (98.2 to 100.0) | 100 (98.2 to 100.0) |
| Serogroup W | 100 (97.9 to 100.0) | 100 (98.1 to 100.0) |
| Serogroup Y | 99 (96.0 to 99.71) | 100 (98.3 to 100.0) |
Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 68 (60.5 to 73.9) | 63 (55.4 to 69.2) |
| Serogroup C | 88 (82.3 to 92.0) | 89 (84.1 to 93.4) |
| Serogroup W | 93 (88.7 to 96.7) | 96 (91.3 to 98.0) |
| Serogroup Y | 91 (85.8 to 94.3) | 95 (90.6 to 97.3) |
Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 100 (98.1 to 100.0) | 98 (94.3 to 99.2) |
| Serogroup C | 100 (98.1 to 100.0) | 100 (98.1 to 100.0) |
| Serogroup W | 100 (98.0 to 100.0) | 100 (98.0 to 100.0) |
| Serogroup Y | 100 (98.2 to 100.0) | 99 (97.3 to 99.99) |
Geometric Mean Ratios(GMRs) of GMTs against each of the serogroup B indicator strains- H44/76, 5/99, N98/254 \& M10713 were calculated at one month after the fourth vaccination (Day 331) versus pre fourth vaccination(Day 301).
| Ratio | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 17 (13 to 22) | 16 (12 to 20) |
| 5/99 | 9.60 (6.99 to 13) | 12 (8.86 to 16) |
| NZ98/254 | 11 (8.35 to 15) | 12 (9.39 to 16) |
| M10713 | 5.99 (4.20 to 8.54) | 6.75 (4.90 to 9.29) |
Geometric Mean Ratios(GMRs) of GMTs against each of the serogroups A,C,W-135 \& Y were calculated at one month after the fourth vaccination (Day 331) versus pre fourth vaccination (Day 301).
| Ratio | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 16 (13 to 21) | 8.75 (6.69 to 11) |
| Serogroup C | 11 (8.86 to 14) | 7.79 (6.25 to 9.71) |
| Serogroup W | 13 (10 to 16) | 9.44 (7.52 to 12) |
| Serogroup Y | 9.75 (8.00 to 12) | 8.97 (7.36 to 11) |
Percentage of subjects with four-fold increase in hSBA titers against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331) over pre-fourth vaccination (Day 301). This outcome measure applies to only groups rMenB+ACWY and rMenB as the serogroup B indicator strains were assessed only for these two groups. For serogroup B strains, 4-fold increase in titers was defined as post 4th vaccination titer ≥8 (if pre 4th vaccination titer was \<2) or post 4th vaccination titer ≥ 4 x pre 4th vaccination titer (if pre 4th vaccination titer was ≥2).
| Percentage of subjects | rMenB+ACWY Group | rMenB Group |
|---|---|---|
| H44/76 | 93 (86.0 to 96.8) | 92 (87.2 to 95.6) |
| 5/99 | 94 (88.2 to 97.6) | 95 (90.9 to 97.9) |
| NZ98/254 | 81 (73.5 to 86.5) | 79 (73.1 to 84.9) |
| M10713 | 58 (48.7 to 66.3) | 60 (52.5 to 67.0) |
Percentages of subjects with four-fold increases in hSBA against each of the N. meningitidis serogroups A,C,W \& Y at one month after the fourth vaccination (Day 331) over pre-fourth vaccination(Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups. For serogroups A, C, W and Y, 4-fold increase in titers was defined as post 4th vaccination titer ≥16 (if pre 4th vaccination titer was \<4) or post 4th vaccination titer ≥ 4 x pre 4th vaccination titer (if pre 4th vaccination titer was ≥4).
| Percentage of subjects | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 90 (84.4 to 93.5) | 71 (64.6 to 77.6) |
| Serogroup C | 88 (81.9 to 92.0) | 77 (70.1 to 82.9) |
| Serogroup W | 89 (83.0 to 93.5) | 84 (77.9 to 89.7) |
| Serogroup Y | 82 (75.6 to 86.9) | 81 (74.4 to 85.8) |
Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 and Y at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 1 (0.01 to 2.6) | 1 (0.01 to 2.7) |
| Serogroup C | 2 (0.8 to 5.6) | 2 (0.5 to 4.9) |
| Serogroup W | 4 (1.5 to 7.3) | 3 (0.8 to 5.9) |
| Serogroup Y | 0 (0.0 to 1.7) | 2 (0.5 to 4.8) |
Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 99 (97.4 to 99.99) | 96 (92.0 to 98.0) |
| Serogroup C | 100 (98.2 to 100.0) | 100 (98.2 to 100.0) |
| Serogroup W | 100 (97.9 to 100.0) | 99 (97.1 to 99.99) |
| Serogroup Y | 98 (95.3 to 99.5) | 99 (97.4 to 99.99) |
Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 65 (58.0 to 71.6) | 58 (50.8 to 64.9) |
| Serogroup C | 77 (70.5 to 82.7) | 85 (79.3 to 89.9) |
| Serogroup W | 92 (86.5 to 95.4) | 91 (85.8 to 94.8) |
| Serogroup Y | 86 (80.1 to 90.2) | 91 (85.8 to 94.3) |
Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
| Percentage of subjects | rMenB+ACWY Group | MenACWY Group |
|---|---|---|
| Serogroup A | 100 (98.1 to 100.0) | 96 (92.4 to 98.3) |
| Serogroup C | 99 (97.1 to 99.99) | 100 (98.1 to 100.0) |
| Serogroup W | 100 (98.0 to 100.0) | 100 (98.0 to 100.0) |
| Serogroup Y | 98 (95.7 to 99.69) | 99 (97.3 to 99.99) |
Number of subjects with solicited local and systemic AEs during the 7 days (including the day of vaccination) after any vaccination
| Participants | rMenB+ACWY Group | rMenB Group | MenACWY Group |
|---|---|---|---|
| Any | 235 | 226 | 194 |
| Any local | 220 | 214 | 157 |
| Any Systemic | 217 | 217 | 178 |
| Erythema (vaccination 1) | 101 | 102 | 44 |
| Induration (vaccination 1) | 111 | 102 | 22 |
| Swelling (vaccination 1) | 82 | 86 | 22 |
| Tenderness (vaccination 1) | 162 | 159 | 73 |
| Change in Eating Habits (vaccination 1) | 53 | 47 | 34 |
| Diarrhea (vaccination 1) | 46 | 41 | 42 |
| Irritability (vaccination 1) | 111 | 121 | 87 |
| Persistent Crying (vaccination 1) | 124 | 132 | 85 |
| Rash (vaccination 1) | 19 | 28 | 18 |
| Sleepiness (vaccination 1) | 69 | 78 | 54 |
| Vomiting (vaccination 1) | 14 | 28 | 23 |
| Fever (vaccination 1) | 49 | 54 | 10 |
| Treatment of Pain/Fever (vaccination 1) | 82 | 98 | 25 |
| Erythema (vaccination 2) | 97 | 102 | 47 |
| Induration (vaccination 2) | 99 | 110 | 32 |
| Swelling (vaccination 2) | 78 | 83 | 24 |
| Tenderness (vaccination 2) | 142 | 138 | 66 |
| Change in Eating Habits (vaccination 2) | 46 | 44 | 31 |
| Diarrhea (vaccination 2) | 37 | 36 | 24 |
| Irritability (vaccination 2) | 99 | 95 | 70 |
| Persistent Crying (vaccination 2) | 104 | 108 | 66 |
| Rash (vaccination 2) | 16 | 21 | 13 |
| Sleepiness (vaccination 2) | 51 | 55 | 45 |
| Vomiting (vaccination 2) | 10 | 21 | 17 |
| Fever (vaccination 2) | 48 | 54 | 15 |
| Treatment of Pain/Fever (vaccination 2) | 74 | 91 | 29 |
| Erythema (vaccination 3) | 86 | 96 | 35 |
| Induration (vaccination 3) | 92 | 103 | 30 |
| Swelling (vaccination 3) | 73 | 82 | 19 |
| Tenderness (vaccination 3) | 139 | 128 | 59 |
| Change in Eating Habits (vaccination 3) | 42 | 45 | 33 |
| Diarrhea (vaccination 3) | 24 | 40 | 25 |
| Irritability (vaccination 3) | 83 | 84 | 61 |
| Persistent Crying (vaccination 3) | 90 | 92 | 60 |
| Rash (vaccination 3) | 10 | 11 | 11 |
| Sleepiness (vaccination 3) | 39 | 46 | 39 |
| Vomiting (vaccination 3) | 7 | 27 | 14 |
| Fever (vaccination 3) | 37 | 38 | 25 |
| Treatment of Pain/Fever (vaccination 3) | 57 | 69 | 31 |
| Erythema (vaccination 4) | 73 | 88 | 37 |
| Induration (vaccination 4) | 84 | 93 | 29 |
| Swelling (vaccination 4) | 75 | 74 | 21 |
| Tenderness (vaccination 4) | 126 | 129 | 64 |
| Change in Eating Habits (vaccination 4) | 59 | 45 | 40 |
| Diarrhea (vaccination 4) | 29 | 28 | 23 |
| Irritability (vaccination 4) | 81 | 74 | 57 |
| Persistent Crying (vaccination 4) | 84 | 89 | 56 |
| Rash (vaccination 4) | 11 | 13 | 6 |
| Sleepiness (vaccination 4) | 50 | 37 | 33 |
| Vomiting (vaccination 4) | 15 | 14 | 11 |
| Fever (vaccination 4) | 53 | 46 | 19 |
| Treatment of Pain/Fever (vaccination 4) | 71 | 67 | 31 |
An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.
| Participants | rMenB+ACWY Group | rMenB Group | MenACWY Group |
|---|---|---|---|
| Any | 103 | 116 | 70 |
| Any unsolicited AEs( vaccination 1) | 63 | 62 | 20 |
| Any unsolicited AEs( vaccination 2) | 60 | 69 | 29 |
| Any unsolicited AEs( vaccination 3) | 57 | 63 | 23 |
| Any unsolicited AEs( vaccination 4) | 44 | 58 | 13 |
A serious adverse event is any untoward medical occurrence that at any dose results in death/ is life threatening/requires prolonged hospitalization/Persistent or significant disability/incapacity/congenital anomaly/or birth defect.
| Participants | rMenB+ACWY Group | rMenB Group | MenACWY Group |
|---|---|---|---|
| Any SAEs | 6 | 13 | 11 |
| Any Medically Attended AEs | 177 | 188 | 183 |
| Any AEs leading to premature withdrawal | 0 | 2 | 1 |
Collected over Solicited local and systemic AEs were collected from day 1 (6 hours) upto day 7 after each vaccination. Unsolicited AEs were collected from day 1 to day 7.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rMenB+ACWY Group | 0/249 (0%) | 6/249 (2.4%) | 240/249 (96.4%) |
| rMenB Group | 0/249 (0%) | 13/249 (5.2%) | 232/249 (93.2%) |
| MenACWY Group | 0/246 (0%) | 11/246 (4.5%) | 221/246 (89.8%) |
| Event | rMenB+ACWY Group | rMenB Group | MenACWY Group |
|---|---|---|---|
| BronchiolitisInfections and infestations | 1/249 | 3/249 | 4/246 |
| Pneumonia bacterialInfections and infestations | 1/249 | 3/249 | 1/246 |
| GastroenteritisInfections and infestations | 1/249 | 2/249 | 0/246 |
| PneumoniaInfections and infestations | 0/249 | 2/249 | 1/246 |
| Milk allergyImmune system disorders | 0/249 | 0/249 | 1/246 |
| PertussisInfections and infestations | 0/249 | 0/249 | 1/246 |
| Urinary tract infectionInfections and infestations | 1/249 | 0/249 | 1/246 |
| Skull fractureInjury, poisoning and procedural complications | 0/249 | 0/249 | 1/246 |
| Febrile convulsionNervous system disorders | 0/249 | 0/249 | 1/246 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/249 | 0/249 | 1/246 |
| Event | rMenB+ACWY Group | rMenB Group | MenACWY Group |
|---|---|---|---|
| Injection site painGeneral disorders | 212/249 | 207/249 | 131/246 |
| CryingGeneral disorders | 176/249 | 184/249 | 129/246 |
| IrritabilityPsychiatric disorders | 155/249 | 170/249 | 125/246 |
| Injection site erythemaGeneral disorders | 147/249 | 162/249 | 104/246 |
| Injection site indurationGeneral disorders | 144/249 | 152/249 | 57/246 |
| Injection site swellingGeneral disorders | 130/249 | 138/249 | 56/246 |
| PyrexiaGeneral disorders | 125/249 | 121/249 | 60/246 |
| SomnolenceNervous system disorders | 106/249 | 115/249 | 87/246 |
| Eating disorderPsychiatric disorders | 110/249 | 100/249 | 85/246 |
| DiarrhoeaGastrointestinal disorders | 108/249 | 98/249 | 89/246 |
| Age, Continuous(Days) | rMenB+ACWY Group | rMenB Group | MenACWY Group | Total |
|---|---|---|---|---|
| Mean | 104.0 ± 10.72 | 101.4 ± 10.57 | 102.7 ± 10.9 | 102.7 ± 10.77 |
| Sex: Female, Male(Participants) | rMenB+ACWY Group | rMenB Group | MenACWY Group | Total |
|---|---|---|---|---|
| Female | 120 | 118 | 139 | 377 |
| Male | 132 | 132 | 109 | 373 |
| Race/Ethnicity, Customized(Participants) | rMenB+ACWY Group | rMenB Group | MenACWY Group | Total |
|---|---|---|---|---|
| White | 17 | 20 | 17 | 54 |
| Other | 235 | 230 | 231 | 696 |
Ran from Jun 2014 to primary completion in Oct 2016, 28 months.
Results were first posted in Aug 2018, 1 year 10 months after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 28 months is above that.
Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4CMenB vaccine